Peer-reviewed veterinary case report
Effectiveness of H3N8 flu vaccine in young beagle dogs after exposure
By Deshpande, Muralidhar S et al.·Published in Veterinary therapeutics : research in applied veterinary medicine·2009·Intervet/Schering-Plough Animal Health, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of the efficacy of a canine influenza virus (H3N8) vaccine in dogs following experimental challenge.
- Species:
- dog
Plain-English summary
A group of 6- to 8-week-old beagle puppies were vaccinated against canine influenza virus (CIV) and then exposed to the virus to see how well the vaccine worked. The vaccinated puppies showed fewer signs of respiratory illness and had less virus in their systems compared to those that received a placebo. The vaccine helped the puppies build up antibodies and significantly reduced the severity of their symptoms. Overall, the study found that the CIV vaccine effectively protects dogs from this respiratory virus.
People also search for: dog flu vaccine effectiveness · beagle puppy respiratory illness · canine influenza virus symptoms
Abstract
Canine influenza virus (CIV) subtype H3N8 is an emerging pathogen with sustained horizontal transmission in the dog population in the United States. This study evaluated the efficacy of an inactivated CIV vaccine in 6- to 8-week-old beagle pups challenged with virulent CIV. One group of CIV-seronegative pups was vaccinated with two doses of a CIV vaccine 3 weeks apart; a second group of pups received adjuvanted placebo as a control. Blood samples were collected at various times to determine antibody titers. All pups were challenged with a virulent CIV isolate 13 days after the second vaccination and monitored for clinical signs of respiratory disease, virus shedding, and lung consolidation. Vaccinated pups developed hemagglutination inhibition antibody titers after vaccination. The severity of clinical signs (P < .001) and the magnitude and duration of virus shedding (P < .0001) were significantly lower in vaccinated pups compared with control pups. These results demonstrate that the CIV vaccine used in this study provides protection against virulent CIV challenge in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/20037964/